Comparison of systemic and intramammary dry cow treatments by Contreras B, G. Andres et al.
3259
Comparison of systemic and intramammary dry cow 
treatments
Comparación de terapias sistémicas e intramamarias para el 
periodo seco en vacas lecheras
G. Andres Contreras B,1* Ph.D, Walter M. Guterbock,2 M.Sc, Juan Muñoz R,1 Ing. Agr, 
Phillip M. Sears,1 Ph.D.
1Michigan State University, College of Veterinary Medicine Department of Large Animal Clinical Sciences, 
East Lansing, Michigan, USA. 2denDulk Dairy, Coopersville, Michigan, USA.*Correspondencia:contrera@
cvm.msu.edu
Recibido: Abril de 2011; Aceptado: Mayo de 2012.
ABSTRACT
Objective. To compare four different dry cow treatments (DCT) and establish their effectiveness in 
reducing intramammary infections (IIM). Materials and methods.  DCTs included systemic tylosin 
(12g) alone or accompanied by cefapirine intramammary infusions and or an internal teat sealant. A 
total number of 278 cows at the end of lactation period were randomly assigned to one of 4 dry cow 
treatment groups:  CESE Group (n=89), intramammary cephapirin and teat sealant. TYCESE Group 
(n=84), intramammary cephapirin, tylosin 12 g intramuscular and teat sealant. TYSE Group (n=86), 
12 g intramuscular tylosin and teat sealant; TY Group (n=76) 12 g intramuscular tylosin only. Milk 
samples for culture were collected at dry-off and 1 and 2 weeks after calving.  Somatic cell counts 
(SCC) were taken from Dairy Herd Improvement Association (DHI) tests at dry-off, and the first two 
test days after calving. Results. Bacteria cure rate for Gram-positive intramammary infections (IMI) 
for TYCESE group was 93.6%, CESE group 78.9%, TYSE group 88.2%, and TY group 78.1%. All four 
groups showed a decrease in the SCC upon the first and second test after calving.  Conclusions. The 
use of systemic tylosin in combination with intramammary antibiotics increased DCT effectiveness 
improving the Gram-positive cure rate IMI. Furthermore, systemic tylosin alone plus teat sealant is 
as effective as cephapirin plus teat sealant when used as DCT.
Key words: Dry period, mastitis, tylosin (Source: CAB).
RESUMEN
Objetivo. Comparar 4 tratamientos para el periodo seco (TPS) y establecer su efectividad en reducir 
infecciones intramamarias (IIM). Materiales y métodos. Los TPS incluían tilosina sistémica (12 
g) solamente o acompañada con infusiones intramamarias de cefapirina y/o un sellante interno de 
pezones. Un total de 278 vacas al final de la lactancia fueron asignadas al azar a 1 de 4 grupos de 
tratamiento. Grupo CESE (n=89), cefapirina y sellante interno de pezones. Gupo TYCESE (n=84), 
cephapirina intramamaria, tilosina intramuscular y sellador interno de pezones. Grupo TYSE (n=86), 
tilosina intramuscular y sellante interno de pezones. Grupo TY (n=76) tilosina intramuscular solamente. 
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Muestras de leche de cada cuarto productivo fueron tomadas al momento del secado, y 1 y 2 semanas 
después del parto. Los recuentos individuales de células somáticas (RCS) fueron tomados del control 
lechero (DHI) en sus pruebas de antes del momento de secado, y las primeras dos pruebas  después 
del parto. Resultados. Las tasa de cura bacteriológica para IIM causadas por Gram positivos en 
TYCESE fue de 93.6%, para CESE 78.9%, TYSE 88.2% y TY 78.1%. Todos los grupos de tratamiento 
mostraron una disminución en RCS a la primera y segunda prueba despues del parto en comparación 
con la de secado. Conclusiones. El uso de tilosina en combinación con cefapirina incremento la 
efectividad del TPS, mejorando las tasas de cura de IIM por Gram positivos. Además TYSE fue tan 
efectivo como CESE en la reducción de IIM.
Palabras Clave: Mastitis, periodo seco, tilosina (Fuente: CAB).
 
INTRODUCTION
Dry cow therapy (DCT) is defined as the use of 
antibiotics immediately after the last milking of 
lactation. There are three different approaches 
to DCT. First, intramammary dry treatment alone 
is widely used and very effective in reducing 
intramammary infections (IMI) (1, 2). However, 
low efficacy against some coagulase negative 
staphylococci (CNS) IMI has been demonstrated.
(3) Another approach is systemic dry cow 
therapy, which is relatively inexpensive and easy 
to use but has been reported to be less effective. 
For example, Nickerson et al (4) administered 
tilmicosin subcutaneously and found it to be less 
effective against IMI caused by Staphylococcus 
aureus than intramammary infusions of cephapirin 
or tilmicosin. Finally a combination of systemic 
and intramammary antibiotics can also be 
administered. However, its efficacy depends upon 
the antibiotic class pharmacological characteristics. 
In fact, Erskine et al (5) reported a low efficacy 
against Staphylococcus aureus IMI when using 
oxytetracycline hydrochloride systemically in 
combination with intramammary cephapirin 
benzathine. The low efficacy of this treatment 
could have been related to the poor diffusion of 
oxytetracycline into the mammary gland.
The use of tylosin as systemic DCT was 
reported to be as effective as intramammary 
infusion with a preparation with beta lactams 
and streptomycin against CNS (6). However, 
combined DCT including systemic tylosin has not 
been previously reported. This antibiotic belongs 
to the macrolide family of antibiotics. One of the 
main advantages of this type of antimicrobials 
is an excellent diffusion into the mammary 
gland related to its basic pK (pH at which 
concentrations of dissociated and undissociated 
antibiotic are equal), which results in a very 
high milk to plasma concentration ratio of 5:1 
(7,8). Once the macrolides are in milk they are 
virtually trapped inside the mammary gland. 
The objective of this study was to compare four 
different DCTs and establish the effectiveness 
of systemic (intramuscular) tylosin therapy 
as DCT at quarter level when was added to 
intramammary infusion of cephapirin, a teat 
sealant, or alone as systemic DCT.
MATERIALS AND METHODS
Study site. Cows on a large commercial farm 
in Michigan were selected.  Every week, for two 
months, and after confirming their gestation to be 
greater than 150 days, a group of Holstein cows 
in their second, third or fourth lactation due to go 
dry were assigned to one of four DCT groups. A 
completely randomized design that included three 
treatments and a control was used (Table 1). 
Table 1. Summary of gram-positive intramammary 
infections by treatment groups at cow and 
quarter level.
Treatment1
CESE TYCESE TYSE TY
Cows Enrolled 75 71 72 60
Cows with IMI at dry-off 
(% cows infected)
30 
(40%)
28 
(39%)
33 
(45%)
32 
(53%)
Cow cured after DCT 
(% cows cured)
20 
(66%)ab
21 
(75%)a
17 
(51%)ab
15 
(46%)b
Cows with new IMI 
after calving 4 4 6 5
Quarters Enrolled 289 271 276 226
Non-functional quarters 11 13 12 14
Quarters infected at 
dry-off (% quarters 
infected)
57 
(19.7%)b
47
(17.3%)b
68 
(24.6%)a
73 
(32.3%)a
Quarters cured after 
DCT (% quarters cured)
45 
(78.9%)b
44 
(93.6%)a
60 
(88.2%)a
57 
(78.1%)b
1Treatment designations: CESE cephapirin 300 mg intramammary 
and Orbeseal® (4 g of internal teat sealant containing 65% bismuth 
subnitrate); TYCESE: tylosin 12 g intramuscular, cephapirin 300 mg 
intramammary, and Orbeseal®; TYSE: Tylosin 12 g intramuscular and 
Orbeseal®; TY: tylosin 12 g intramuscular. abDifferent superscripts within 
each row differ (p<0.05).
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Treatments. Treatment CESE (n=89 cows), 
reflecting standard practice on the farm, was 
used as control.  After the last milking of 
lactation, animals were first infused in each 
productive quarter with a commercial preparation 
of 300 mg of cephapirin (Tomorrow®, Fort 
Dodge, Ft Dodge, Iowa, USA) intramammary 
and then with 4 g of commercially available 
internal teat sealant containing 65% bismuth 
subnitrate (Orbeseal®, Pfizer. New York, New 
York, USA). Treatment TYCESE (n=84 cows) 
animals were first infused in each productive 
quarter with cephapirin intramamary 300 
mg, then injected intramuscularly with tylosin 
(Tylosin, Agripharma. Westlake, Texas, USA) 
12 g and finally were infused with teat sealant. 
Group TYSE (n=86 cows) animals received 
tylosin 12 g intramuscular and then teat sealant 
was infused in each productive quarter. Group 
TY (n=76 cows) animals received 12 g tylosin 
intramuscularly. Intramammary infusions were 
administered by the partial insertion technique.
Prior to instillation. All teat ends were prepared 
following the farm’s milking preparation routine 
that included a predip solution containing 
0.1% iodine, after which the dry teat end was 
disinfected with a cotton pad containing 70% 
isopropyl alcohol.  Intramuscular injections were 
given in the neck, splitting the dose between 
two different sites. Tylosin dosage calculation 
was based in 20 mg/Kg dose for a 600 Kg 
cow (average weight for mature cows on this 
commercial farm).
Milk samples. Quarter milk samples were taken 
following National Mastitis Council guidelines (9) 
from all functional quarters at dry-off and at 1 and 
2 wks after calving. Samples were immediately 
processed at the dairy’s on-farm laboratory. A 
10 mL aliquot from each sample was cultured on 
blood agar containing 0.5% esculin at 37°C for 
24 h. Colonies were tentatively identified as CNS, 
streptococci, Staphylococcus aureus, coliforms 
or others; a presumptive diagnosis of CNS, 
streptococci, coliform, or other pathogens was 
made, based on colony growth, morphology and 
appearance, pattern of hemolysis, and catalase 
reaction. Staphylococcal isolates were tested for 
coagulase production with the tube coagulase 
test. Gram-negative bacteria were plated on 
MacConkey agar to facilitate identification. Only 
CNS, streptococci and S. aureus were included 
in data analysis.
This approach was based on the label use for 
cephapirin (Tomorrow®) and Tylosin sold in the 
United States at the time of the trial, not on 
their antibacterial activity. A cow was considered 
infected if at least one productive quarter had an 
IMI. A quarter was considered infected if five or 
more cfu of the same kind were identified, and 
was considered contaminated if three or more 
different colony types were present. Post calving 
samples were used to establish bacterial cure. A 
cow was considered cured if she had an IMI at 
dry-off and all productive quarters were negative 
at both samples post-calving. A cow was not 
cured if she had an IMI at dry-off and continued 
with the same quarter(s) infected with the same 
species at first and second test after calving. A 
quarter was considered cured if it was positive 
at dry-off and negative in first and second post-
calving samples.  It was considered not cured if 
it was positive to the species found at dry-off and 
again 1 and/or 2 wk after calving. A quarter was 
considered newly infected if it was negative at 
dry-off and positive at 1 and 2 wk after calving
Dairy Herd Improvement (DHI) tests were 
recorded to monitor SCC.  
The last test of lactation was considered the dry-
test, and then linear SCC scores from subsequent 
monthly tests, were used to determine changes 
in SCC. Milk production records were collected 
by DHI personnel and total production was 
established as projected to 305 days mature 
equivalent (ME) by a herd management software 
(DairyComp®, Herd Management software, Valley 
Agricultural Software, Tulare, California, USA) 
based on milk production at DHI test taken 
between 180 and 200 days in milk (DIM) after 
calving following the DCT assigned. A composite 
milk sample was taken at calving to perform 
antibiotic residue test (Delvotest® system, DMS 
food specialties, Parsippany, New Jersey, USA). 
Cows with less than 30 d dry were excluded 
because of antimicrobial residue issues that 
required milk withdrawal. Cows with more than 
100 d dry were also excluded. Of the 335 cows 
enrolled in the dry cow treatment trial, 278 
had complete records and were included in the 
results. 
Analysis of results. Culture results were 
analyzed with the PROC GLIMMIX procedure 
for binary variables (SAS Inst. Inc., Cary, North 
Carolina, USA). Results were blocked by sampling 
date and the random statement was assigned 
to quarter within cow as experimental unit. The 
SCC scores were analyzed as repeated measures 
using a mixed model procedure (PROC MIXED; 
SAS Inst. Inc., Cary, North Carolina, USA) 
following the equation:
Yijk = µ + Gi + Ij +Gi * Ij + Sk +Sk*Gi + Sk*Ij + 
Sk*Gi*Ij + Eijk
Where Yijk is the dependent variable SCC score 
for a cow in group i, with infection status j, at 
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sample k as repeated measure, and Eijk is the 
random error assumed to be correlated. The 
Satterthwaite’s method for estimating degrees 
of freedom was used. Significance level was set 
at alpha=0.05.
RESULTS
A total of 123 cows (44%) had IMI at dry-off 
and no differences in infection rate were found 
when comparing all four groups. Percentages 
of cows with IMI within each treatment group 
were as follows CESE 40%, TYCESE 39%, TYSE 
45% and TY 53%. Cure rates at cow level were 
significantly higher for group TYCESE (75%) 
when compared to group TY (46%). Group CESE 
had a (66%) cure rate and TYSE (51%) and this 
difference was not significant. A summary of 
these results is shown in table 1. Despite of the 
use of antibiotics, residue tests were negative on 
all samples taken after calving.  
A total of 245 quarters (23% overall) were found 
infected with CNS, streptococci or S. aureus. IMI 
rates by quarters at dry-off are shown in table 
1. Group TY had 32.3% infected quarters and 
group TYSE had 24.6%, both were significantly 
higher (p<0.05) than TYCESE 17.3% and CESE 
19.7%. Gram-positive bacterial infection results 
are summarized in table 2. 
Table 2. Summary of gram-positive culture results by 
treatment groups at quarter level.
Treatment 1
CESE TYCESE TYSE TY
CNS2 quarters infected at dry-
off (% quarters infected)
41 
(72%)a
27 
(57%)b
28 
(41%)b
58 
(79%)a
CNS % quarters cured after 
DCT 73%a 92%b 89%b 72%a
Streptococci quarters infected 
at dry-off (% quarters infected)
14 
(24%)
18 
(38%)
34 
(50%)
14 
(19%)
Streptococci quarters cured 
after DCT 100% 94% 91% 100%
S aureus quarters infected at 
dry-off 2 2 6 1
1Treatment designations: CESE cephapirin 300 mg intramammary 
and Orbeseal® (4 g of internal teat sealant containing 65% bismuth 
subnitrate); TYCESE: tylosin 12 g intramuscular, cephapirin 300 mg 
intramammary, and Orbeseal®; TYSE: Tylosin 12 g intramuscular and 
Orbeseal®; TY: tylosin 12 g intramuscular.
2CNS= coagulase negative staphylococci
ab Different superscripts within each row differ (p<0.05).
CNS accounted for 62.9% of the infections, 
streptococci for 32.6% and S. aureus for 4.5%. 
The staphylococcal infection rate was significantly 
higher in group TY when compared to TYCESE 
and TYSE (p<0.05) (Table 1). Infections caused 
by S aureus were found in 2 quarters of group 
CESE, 2 quarters of TYCESE, 6 quarters of TYSE 
and 1 quarter of TY. With such a small number 
of infections it was not possible to establish 
differences among groups. Furthermore, IMI 
with S aureus exhibit intermittent shedding 
that requires at least 3 multiple samplings to 
identify a truly infected quarter and this trial 
only collected 1 sample at dry-off (10).  Further 
studies are needed to evaluate tylosin efficacy 
alone or in combination with other antibiotics and 
or teat sealants against S. aureus IMI. Coliform 
infections were found in 5 quarters from 3 
different cows at the moment of dry-of (results 
not shown). These infections were cleared after 
parturition. 
Bacterial cure rates for gram-positive bacteria by 
quarters are shown in table 2. TYCESE had the 
highest cure rate (93.6%) and was significantly 
different (p<0.05) from TY (78.1%) and CESE 
(78.9%). No difference was found when TYCESE 
was compared to Group TYSE (88.2%). New 
infections rates were low, group CESE (1.8%), 
group TYCESE (2.6%), group TYSE (2.9%) and 
group TY (3.3%). When comparing cure rates by 
bacteria type (Table 1) all four treatments had good 
efficacy against streptococcal infections, but there 
were differences in cure rates for staphylococcal 
infections. Group TYCESE had higher cure rates 
(92.5%) than CESE (73.17%) and TY (72.4%) 
(p<0.05). 
All four treatments resulted in a decrease in the 
SCC at the first and second test after calving and 
no statistical differences were observed among 
them (Figure 1). Milk production at test date 
between 180 to 200 DIM was analyzed using 305 
ME value. Milk production for each treatment 
group was as follows: TYCESE 23.910±5.686 lb, 
CESE 22.056±5.104 lb, TY 21.900 ± 4.278 lb 
and TYSE 21.791± 4.086 lb. When the difference 
between arithmetic mean of previous and 
current lactations was calculated for all groups, 
no significant differences were found. 
Figure 1. logSCC at dry-off, first test and second test 
after calving for each treatment group. Values 
are means ± SEM.
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DISCUSSION
Bacterial cure rates for systemic tylosin (group 
TY 78.1%) are similar to those obtained by 
McDougall et al (11) in New Zealand, who 
administered tylosin intramuscularly to treat 
clinical mastitis during lactation and obtained 
82% cure rates for Gram-positive infections. 
Systemic tylosin as DCT alone (TY) or plus teat 
sealant (TYSE) is as effective as intramammary 
cephapirin plus teat sealant (Group CESE 
78.9%) to reduce IMI. 
The randomization was effective in distributing 
IMI among groups at cow level, but was 
ineffective at quarter level generating a bias, 
observed in a higher number of quarter infections 
and a lower cure rate for the TY group. An ideal 
randomization would have included blocking after 
culturing quarters but this process would have 
represented major logistical problems on this 
commercial farm. However, all four DCTs were 
effective in reducing IMI. 
Nickerson et al (4) used a systemic macrolide 
(tylmicosin) to treat IMI during the dry period 
reporting low cure rates against staphylococcal 
infections, however, the dose (1 mg/Kg) used 
by the authors does not have bacteriocidal 
activity, and subcutaneous administration could 
have delayed antibiotic distribution. Tylosin’s 
effectiveness during this trial could be related 
to its distribution properties and the fact 
that a higher than recommended dose with a 
single injection was used. Tylosin’s peak milk 
concentration was reported to be 10 µg/ml after 
a single injection at a dose of 20 mg/Kg b.w. (12) 
and 18 µg/ml after three repeated injections at 
a dose of 10 mg/Kg b.w (13). 
In the present work, tylosin’s dose was based on 
average calving weight for cows (600 Kg) at 20 
mg/Kg. Despite of the relative high dose used, 
antibiotic residues were not found in the composite 
samples taken at calving. It is presumable that 
peak milk concentration in tylosin treated 
animals was higher than previously reported, 
therefore achieving bactericidal activity, which 
was observed for macrolides when used in high 
concentrations (14).
When analyzing cure rate by bacteria type, 
intramammary treatment alone could have been 
limited in its ability to eliminate infections during 
the dry period (CESE 73.2%). Similar to what 
was reported by Bolurchi et al (6) inclusion of 
systemic tylosin in DCT increased cure rates for 
CNS IMI. Because CNS could be responsible of 
nearly half of the IMI during the dry period, an 
increase in the cure rate towards this bacteria 
type obtained by the addition of systemic 
tylosin to the intramammary DCT would have an 
important economic impact (15). 
In conclusion, DCT remains a cost-effective 
measure compared with no treatment at dry-
off (3,16,17). The use of systemic tylosin in 
combination with the intramammary cephapirin 
increased the effectiveness of intramammary 
DCT against Gram-positive IMI. Though, inclusion 
of a combined systemic and intramammary 
treatment has to be based on an economic 
analysis of the increased cost of such therapy 
versus its higher effectiveness. Interestingly, 
there were no differences between the use of 
tylosin plus teat sealant and intramammary 
cephapirin plus teat sealant at dry-off. Therefore 
the use of these 2 DCT options may be based 
on the logistical advantages of each treatment 
protocol. Tylosin may have the advantage 
of being easier to administer in dairies with 
confinement housing where headlocks are 
available to treat large groups of animals. Finally, 
it is important to mention that adding the teat 
sealant to the systemic treatment with tylosin at 
dry-off improved the response of the treatment. 
Further studies are needed to validate this 
effect in other dairy herds and to test the use of 
extended therapy with tylosin particularly when 
selective DCT is used.
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